[The findings showed that PBT434 passed the blood-brain barrier and inhibited the alpha-synuclein protein which when aggregated in the brain is a pathological hallmark of Parkinsonian conditions and is considered an important biologic target for treating these neurodegenerative diseases.]
More info from the P1.
- Forums
- ASX - By Stock
- ATH
- PBT434 inhibits alpha- synuclein in the brain.
PBT434 inhibits alpha- synuclein in the brain.
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $18 | 6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
28 | 17696248 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 129653156 | 26 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 17696248 | 0.003 |
69 | 89423179 | 0.002 |
28 | 140710099 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 129653156 | 26 |
0.005 | 18848455 | 22 |
0.006 | 22089363 | 18 |
0.007 | 54073650 | 25 |
0.008 | 42418463 | 31 |
Last trade - 11.56am 04/10/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |